Contrast media reactions rarely happen, study finds
Concerns about the potential adverse reactions of patients to iodinated and gadolinium-based contrast agents used with CT and MRI may be more perceived than real, according to Mayo Clinic researchers.
Concerns about the potential adverse reactions of patients to iodinated and gadolinium-based contrast agents used with CT and MRI may be more perceived than real, according to Mayo Clinic researchers.
Dr. Christopher H. Hunt and colleagues in Rochester, MN, reviewed 456,930 episodes of contrast media administration. From this base, 522 cases of mostly mild adverse effects were identified. Reactions included nausea, vomiting, and skin rashes. Only 16 cases, 10 severe reactions to low-osmolar iodinated agents and six to gadolinium, needed transfer to an emergency department for further observation and treatment. One patient died, but possibly due to unrelated causes. Pretreatment with corticosteroids helped bring down the incidence of adverse effects (AJR 2009;193[4]:1124-1127). Adverse contrast reactions can occur, but they are rarely severe and most require only observation and supportive care, Hunt said.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
